03.09.16
Smithers Avanza’s Bioanalytical Services Division has completed an expansion of its bioanalytical lab that will accommodate 33% percent more staff to support client needs during the development of large molecule biologic therapies.
“Rising demand for testing from our clients, which include some of the world’s largest biopharmaceutical companies, has resulted in the company more than doubling our scientific and support staff year over year,” said Ira DuBey, executive vice president, Bioanalytical Services Division, Smithers Avanza. “Expanding our lab space helps us create capacity so that we can continue to support our clients with the highest level of service.”
The company has added several new staff members, including senior scientific and support personnel for client development of large molecule biologics including immuno-oncology drugs and combination therapies. Additionally, the company acquired new liquid handling robotics instrumentation and another Singulex instrument to support testing of high sensitivity biomarker and pharmacokinetic assays.
“Rising demand for testing from our clients, which include some of the world’s largest biopharmaceutical companies, has resulted in the company more than doubling our scientific and support staff year over year,” said Ira DuBey, executive vice president, Bioanalytical Services Division, Smithers Avanza. “Expanding our lab space helps us create capacity so that we can continue to support our clients with the highest level of service.”
The company has added several new staff members, including senior scientific and support personnel for client development of large molecule biologics including immuno-oncology drugs and combination therapies. Additionally, the company acquired new liquid handling robotics instrumentation and another Singulex instrument to support testing of high sensitivity biomarker and pharmacokinetic assays.